A Study Conducted Using Electronic Health Record data from a collective of us health care systems Agonist (GLP-1 ra) therapy within one year. Discontinuation rates were significant Higher and Reinitiation Rates were Significant Lower for Patients without Type 2 Diabetes.

GLP-1 ras are used for weight management and glycemic control, with evidence suggesting that continued use is Necessary for Sustained Benefits. Concerns related to cost, tolerability, and access may be contributing to high discontinuation rates. Previous Studies have reported widely varying discontinuation rates, but data on reinitiation patterns Remain Limited.

In the study, “discontinuation and reinitiation of dual-Labeled GLP-1 Receptor agonists agonists amon us adults with overweight or obesity,” Published in Jama Network OpenResearchers investigated the rates at which people stopped using the popular weight loss drugs.

A retrospective cohort analysis include 125,474 adults with overweight or obesity who initiated treatment with liraglutide, semaglutide, or tirzepatide between januen janury 1, 2018, and decision 2023. Eligible Patients Had a Body Mass Index of 27 or Higher, A Weight Measurement Within 60 Days Before Initiation, and Regular Health Care Interactions in the Previous Year.

Discontinuation was defined as 60 days without any glp-1 ra-on hand. Reinitiation was defined as the first film of any GLP-1 ra-after discontinuation. Patients were followed for up to two years for discontinuation and two additional years for reinitiation. Time-to-Event Outcomes Were Assessed Using Kaplan-Meer Models and Cox Proportional Hazards Regression.

Within one year, 46.5% of patients with type 2 diabetes and 64.8% with type 2 diabetes discontinued GLP-1 Ra Ra Therapy. Within two years, discontinuation rates increase to 64.1% and 84.4%, respectively. Gastrointestinal Adverse events were linked to the discontinuation rates.

Among 41,792 Patients Who Discontinued and Had a Weight Measurement at Discontinuation, 47.3% of PATINETS with Type 2 Diabetes and 36.3% with Type 2 Diabetes Reinitiated Thercessed Thercessed Therppy with Aone. Weight regain was significantly associated with reinitiation, with a 1% weight gain increasing the hazard by 2.3% for patients with type 2 diabetes and 2.8% for there. Patients aged 65 years or older was liekely to reinitiate treatment.

GLP-1 ra-discontinuation rates were high, particularly for patients with Type 2 diabetes, who also hado reinitiation rates. Weight loss during treatment was associated with lower discontinuation, white weight regain after discontinuation was linked to higher reinitiation.

© 2025 Science X Network